A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

April 25, 2023

Study Completion Date

April 25, 2023

Conditions
Solid TumorLymphomaOsteosarcomaEwing SarcomaRhabdomyosarcomaNon-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Interventions
DRUG

Surufatinib in combination with Gemcitabine

Surufatinib in combination with Gemcitabine

Trial Locations (11)

15224

UPMC Children's Hospital of Pittsburgh, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Hospital, Washington D.C.

21287

Johns Hopkins University, Baltimore

35233

Children's Hospital of Alabama, Birmingham

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children, Indianapolis

63110

Washington University School of Medicine, St Louis

75390

The University of Texas Southwestern Medical Center, Dallas

92868

Childrens Hospital Orange County, Orange

98105

Seattle Children's Hospital, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Hutchmed

INDUSTRY

NCT05093322 - A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | Biotech Hunter | Biotech Hunter